Home › Acute Lymphocytic Leukemia
Pag-aaral pangklinika para sa Acute Lymphocytic Leukemia na nagre-recruit sa U.S.
8 pag-aaral para sa Acute Lymphocytic Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
Ayos sa estado
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05254743Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07566364Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT06580002Halt Aging in Survivors of Blood Cancers
Nagre-recruit
Edad 50 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT07292272211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 1/2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT03670966Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 26 · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT05865301A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update May 28, 2026 · NCT03219450Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Nagre-recruitPhase 2
Edad 1 hanggang 60 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT03970096Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.